HER2-targeted therapy influences CTC status in metastatic breast cancer.

Thomas M DeutschSabine RiethdorfCarlo FremdManuel FeisstJuliane NeesChiara FischerAndreas D HartkopfKlaus PantelAndreas TrumppFlorian SchützAndreas SchneeweissMarkus Wallwiener

Published in: Breast cancer research and treatment (2020)

HER2-targeted therapy seems to reduce the overall CTC count in patients with MBC. This should be taken into account when CTC status is used as an indicator for aggressive or indolent metastatic tumor disease.

Keyphrases

metastatic breast cancer
circulating tumor cells
circulating tumor
squamous cell carcinoma
small cell lung cancer
hodgkin lymphoma
cell free